Variability in total serum IgE over 1 year in severe asthmatics

[en] Background: Immunoglobulin E (IgE) is the treatment target of omalizumab, a monoclonal antibody indicated in the treatment of severe allergic asthma. Long-term variability of serum total IgE (sIgE tot ) in asthmatics remains poorly documented. Methods: In this prospective study, sIgE tot levels were measured over 1 year at 7 time points in 41 severe asthmatics treated with high-dose of inhaled corticosteroids and long-acting β 2 agonists. 33 patients were atopic based on at least one positive RAST to common aeroallergens. Patients were divided into three groups according to their baseline sIgE tot level: low (< 76 IU/mL; n = 10), intermediate (76-700 IU/mL; n = 20) or high (> 700 IU/mL; n = 11). Patients also completed the six-item Juniper Asthma Control Questionnaire (ACQ 6 ). The sIgE tot variability and factors predictive for this variability were studied, as well as ACQ 6 outcomes. Results: The variation in sIgE tot level was mostly the consequence of between patient-variability, which represented 96%, 71% and 96% of the total variability in the low, intermediate and high sIgE tot subgroups, respectively. The residual within-patient variability was therefore limited. In 10/41 patients, sIgE tot levels increased or decreased, for at least one visit, beyond the predefined range of the subgroups to which they were assigned (< 76 IU/mL; 76-700 IU/mL; > 700 IU/mL). There was a significant but weak correlation between sIgE tot and ACQ 6 score over all time points (r = 0.15, p = 0.02), but sIgE tot failed to associate with severe exacerbation. sIgE tot decreased by 3% with any additional year of age for the whole group (p = 0.01) and increased by 5% per one unit of allergen exposure score in atopic patients (p = 0.002). Conclusion: In severe asthmatics, limited within-patient variability of sIgE tot levels was observed over 1 year as opposed to marked between-subject variability. sIgE tot decreases with age. Variation in sIgE tot weakly associates with asthma control but not with exacerbation. © 2019 The Author(s).

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

Louis, Renaud ; Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie

Pilette, C.; Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, Brussels, 1200, Belgium

Michel, O.; CHU Brugmann, Place A.Van Gehuchten 4, Brussels, 1020, Belgium

Michils, A.; CUB Hôpital Erasme, Route de Lennik 808, Brussels, 1070, Belgium

Brusselle, G.; UZ Gent, Corneel Heymanslaan 10, Ghent, 9000, Belgium

Poskin, A.; Novartis Pharma, Medialaan 40, Vilvoorde, 1800, Belgium

Van Schoor, J.; Novartis Pharma, Medialaan 40, Vilvoorde, 1800, Belgium

Denhaerynck, K.; Matrix45, LLC, 6159 West Sunset Road, Tucson, AZ 85743, United States, University of Basel, Basel, Switzerland

Vancayzeele, S.; Novartis Pharma, Medialaan 40, Vilvoorde, 1800, Belgium

Abraham, I.; Matrix45, LLC, 6159 West Sunset Road, Tucson, AZ 85743, United States

Gurdain, S.; Novartis Pharma, Medialaan 40, Vilvoorde, 1800, Belgium

Language :

English

Title :

Variability in total serum IgE over 1 year in severe asthmatics

Publication date :

2019

Journal title :

Allergy, Asthma and Clinical Immunology

ISSN :

1710-1484

eISSN :

1710-1492

Publisher :

BioMed Central Ltd.

Volume :

Issue :

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 12 November 2019

Statistics

Number of views

35 (1 by ULiège)

Number of downloads

44 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Gould HJ, Sutton BJ, Beavil AJ, Beavil RL, McCloskey N, Coker HA, Fear D, Smurthwaite L. The biology of IGE and the basis of allergic disease. Annu Rev Immunol. 2003;21:579-628.
Asai K, Kitaura J, Kawakami Y, Yamagata N, Tsai M, Carbone DP, Liu FT, Galli SJ, Kawakami T. Regulation of mast cell survival by IgE. Immunity. 2001;14:791-800.
Kalesnikoff J, Huber M, Lam V, Damen JE, Zhang J, Siraganian RP, Krystal G. Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival. Immunity. 2001;14:801-11.
Manise M, Holtappels G, Van CK, Schleich F, Bachert C, Louis R. Sputum IgE and cytokines in asthma: relationship with sputum cellular profile. PLoS ONE. 2013;8:e58388.
Barbee RA, Halonen M, Kaltenborn W, Lebowitz M, Burrows B. A longitudinal study of serum IgE in a community cohort: correlations with age, sex, smoking, and atopic status. J Allergy Clin Immunol. 1987;79:919-27.
Sherrill DL, Halonen M, Burrows B. Relationships between total serum IgE, atopy, and smoking: a twenty-year follow-up analysis. J Allergy Clin Immunol. 1994;94:954-62.
Bousquet J, Rabe K, Humbert M, Chung KF, Berger W, Fox H, Ayre G, Chen H, Thomas K, Blogg M, Holgate S. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med. 2007;101:1483-92.
Mummadi SR, Hatipoglu US, Gupta M, Bossard MK, Xu M, Lang D. Clinically significant variability of serum IgE concentrations in patients with severe asthma. J Asthma. 2012;49:115-20.
Hatipoglu U, Subramanian A, Campbell T, Rice R, Mummadi S, Hu B, Lang DM. Intrasubject variability in total IgE levels in patients with moderate to severe persistent allergic asthma over 1 year. J Allergy Clin Immunol Pract. 2016;4:691-6.
Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, Boulet LP, Brightling C, Chanez P, Dahlen SE, Djukanovic R, Frey U, Gaga M, Gibson P, Hamid Q, Jajour NN, Mauad T, Sorkness RL, Teague WG. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343-73.
Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309-16.
Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the Asthma Control Questionnaire. Respir Med. 2005;99:553-8.
Capron M, Capron A. Immunoglobulin E and effector cells in schistosomiasis. Science. 1994;264:1876-7.
Pien GC, Orange JS. Evaluation and clinical interpretation of hypergammaglobulinemia E: differentiating atopy from immunodeficiency. Ann Allergy Asthma Immunol. 2008;100:392-5.
Manise M, Bakayoko B, Schleich F, Corhay JL, Louis R. IgE mediated sensitisation to aeroallergens in an asthmatic cohort: relationship with inflammatory phenotypes and disease severity. Int J Clin Pract. 2016;70:596-605.
Demarche SF, Schleich FN, Paulus VA, Henket MA, Van Hees TJ, Louis RE. Asthma control and sputum eosinophils: a longitudinal study in daily practice. J Allergy Clin Immunol Pract. 2017;5:1335-43.
Schleich FN, Chevremont A, Paulus V, Henket M, Manise M, Seidel L, Louis R. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J. 2014;44(1):97-108. https://doi.org/10.1183/09031936.00201813
Denlinger LC, Phillips BR, Ramratnam S, Ross K, Bhakta NR, Cardet JC, Castro M, Peters SP, Phipatanakul W, Aujla S, Bacharier LB, Bleecker ER, Comhair SA, Coverstone A, DeBoer M, Erzurum SC, Fain SB, Fajt M, Fitzpatrick AM, Gaffin J, Gaston B, Hastie AT, Hawkins GA, Holguin F, Irani AM, Israel E, Levy BD, Ly N, Meyers DA, Moore WC, Myers R, Opina MT, Peters MC, Schiebler ML, Sorkness RL, Teague WG, Wenzel SE, Woodruff PG, Mauger DT, Fahy JV, Jarjour NN. Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations. Am J Respir Crit Care Med. 2017;195:302-13.
Chapman KR, Cartier A, Hebert J, McIvor RA, Schellenberg RR. The role of omalizumab in the treatment of severe allergic asthma. Can Respir J. 2006;13(Suppl B):1B-9B.
Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, Lal P, Arron JR, Harris JM, Busse W. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187:804-11.
Mouthuy J, Detry B, Sohy C, Pirson F, Pilette C. Presence in sputum of functional dust mite-specific IgE antibodies in intrinsic asthma. Am J Respir Crit Care Med. 2011;184:206-14.
Takhar P, Corrigan CJ, Smurthwaite L, O'Connor BJ, Durham SR, Lee TH, Gould HJ. Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma. J Allergy Clin Immunol. 2007;119:213-8.
Ying S, Humbert M, Meng Q, Pfister R, Menz G, Gould HJ, Kay AB, Durham SR. Local expression of epsilon germline gene transcripts and RNA for the epsilon heavy chain of IgE in the bronchial mucosa in atopic and nonatopic asthma. J Allergy Clin Immunol. 2001;107:686-92.